Xenetic Biosciences, Inc., a biopharmaceutical company, is focused on advancing XCART, a customized chimeric antigen receptor T (CAR T) platform technology designed to target patient-specific tumor neoantigens. The company is headquartered in Framingham, Massachusetts.
| Revenue (TTM) | $3.19M |
| Gross Profit (TTM) | $3.19M |
| EBITDA | $-5.75M |
| Operating Margin | -62.20% |
| Return on Equity | -37.00% |
| Return on Assets | -21.80% |
| Revenue/Share (TTM) | $1.69 |
| Book Value | $3.23 |
| Price-to-Book | 0.97 |
| Price-to-Sales (TTM) | 2.17 |
| EV/Revenue | 0.069 |
| EV/EBITDA | 1.03 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 36.00% |
| Shares Outstanding | $2.29M |
| Float | $1.78M |
| % Insiders | 10.24% |
| % Institutions | 7.38% |
Volatility is currently contracting